Allarity Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Allarity Therapeutics generated cash of -$12,745,000, which is more than the previous year. Cash used in financing activities reached the amount of $10,995,000 last year. Net change in cash is therefore -$1,863,000.
Cash Flow
| 2015 | -2.02M | 1.66M | 3.77M |
|---|---|---|---|
| 2017 | -1.34M | -127.96K | 1.15M |
| 2019 | -10.11M | 229K | 11.20M |
| 2020 | -7.25M | -3K | 6.03M |
| 2021 | -15.05M | 1M | 33.81M |
| 2022 | -16.81M | 791K | -1.31M |
| 2023 | -12.74M | 0 | 10.99M |
ALLR Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.02M | 19.55M | 298K | 1.52M | 237K | 2.07M | 0 |
Operating activities | |||||||
Net income | -11.90M | -16.05M | -26.64M | -5.07M | -14.4M | -4.89M | -1.14M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 37K | 60K | 106K | 46K | 51K | 8.70K | 265.21K |
Stock-based compensation expense | -71K | 1.75M | 6.36M | 616K | 333K | 2.33M | 0 |
| Deferred income tax benefit | -71K | 1.75M | 6.36M | 616K | 333K | 2.33M | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 95K | -95K | 4.99K | -891.50K |
Inventories | 0 | 0 | 0 | 0 | 1.96M | -62.04K | 0 |
Accounts payable | 2.16M | 6.20M | -1.31M | -62K | 237K | 0 | 0 |
Cash generated by operating activities | -12.74M | -16.81M | -15.05M | -7.25M | -10.11M | -1.34M | -2.02M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -18K | 0 | -3K | -8K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 1.92M |
Cash generated by investing activities | 0 | 791K | 1M | -3K | 229K | -127.96K | 1.66M |
Financing activities | |||||||
Common Stock Issued | 20.29M | 0 | 32.12M | 3.70M | 13.55M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -6.65M | -1.51M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -2.64M | 1M | -2.94M | -533K | 3.54M | 0 | 0 |
Cash used in financing activities | 10.99M | -1.31M | 33.81M | 6.03M | 11.20M | 1.15M | 3.77M |
Net Change In Cash | -1.86M | -17.52M | 19.25M | -1.22M | 1.28M | -1.53M | 0 |
Cash at end of period | 166K | 2.02M | 19.55M | 298K | 1.52M | 536.02K | 0 |
| Data source | Data source | Data source |